Op-Ed by Adial Pharmaceuticals CEO Published in the Daily Progress

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CHARLOTTESVILLE, VA / ACCESSWIRE / May 4, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced today that an op-ed written by William Stilley, CEO of Adial Pharmaceuticals, entitled “America’s real drug problem: Foreign companies make our electronics; should they make our drugs?” was published yesterday in The Daily Progress, a newspaper covering Central Virginia since 1892.

Sign up to follow Adial Pharmaceuticals on Twitter @AdialPharma, or William Stilley on Twitter @BillStilley. To receive Adial Pharmaceuticals updates via e-mail, subscribe here.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ Phase 3 Pivotal Clinical Trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adialpharma.com.

Contact:

Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com

SOURCE: Adial Pharmaceutical, Inc.

View source version on accesswire.com:
https://www.accesswire.com/588236/Op-Ed-by-Adial-Pharmaceuticals-CEO-Published-in-the-Daily-Progress

Staff

Recent Posts

Mobile-health Network Solutions Announces Share Repurchase Program of up to 214,000 Shares

Singapore, Singapore--(Newsfile Corp. - June 5, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or…

2 hours ago

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a…

2 hours ago

Doheny Eye Institute Welcomes Emma Lessieur-Contreras, MD, PhD, as Principal Investigator

Dr. Lessieur-Contreras will continue her groundbreaking research on understanding the early stages of diabetic retinopathy…

2 hours ago

Precision Optics Expands Facilities to Meet Growing Backlog

Company signs lease to move corporate offices and engineering development to Littleton, MA Move allows…

2 hours ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a…

2 hours ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009…

2 hours ago